This evidence is backed up by a study conducted by Hasegawa et al., which found that GLP-1 administration improves dyslipidemia by inhibiting HMG-CoA reductase in T2DM patients [65]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.